• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Galderma

    < Previous 1 2 Next >
    Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation
    From Galderma
    Via Business Wire
    Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends
    From Galderma
    Via Business Wire
    ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
    From Galderma
    Via Business Wire
    EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
    From Galderma
    Via Business Wire
    Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
    From Galderma
    Via Business Wire
    Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
    From Galderma
    Via Business Wire
    Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
    From Galderma
    Via Business Wire
    Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
    From Galderma
    Via Business Wire
    PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
    From Galderma
    Via Business Wire
    Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
    From Galderma
    Via Business Wire
    Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
    From Galderma
    Via Business Wire
    Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
    From Galderma
    Via Business Wire
    AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
    From Galderma
    Via Business Wire
    Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
    From Galderma
    Via Business Wire
    Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
    From Galderma
    Via Business Wire
    Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
    From Galderma
    Via Business Wire
    CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
    From Galderma
    Via Business Wire
    Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
    From Galderma
    Via Business Wire
    Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
    From Galderma
    Via Business Wire
    Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
    From Galderma
    Via Business Wire
    IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
    From Galderma
    Via Business Wire
    Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
    From Galderma
    Via Business Wire
    TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
    From Galderma
    Via Business Wire
    Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
    From Galderma
    Via Business Wire
    Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories
    From Galderma
    Via Business Wire
    Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
    From Galderma
    Via Business Wire
    Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis
    From Galderma
    Via Business Wire
    EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
    From Galderma
    Via Business Wire
    Galderma announces progress with RelabotulinumtoxinA regulatory submissions
    From Galderma
    Via Business Wire
    Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology
    From Galderma
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.